Filtros de búsqueda

Lista de obras de Evandro de Azambuja

11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial

artículo científico publicado en 2017

18F-FDG PET/CT for early prediction of response to neoadjuvant lapatinib, trastuzumab, and their combination in HER2-positive breast cancer: results from Neo-ALTTO.

artículo científico publicado en 2013

2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial

artículo científico publicado en 2013

A pooled analysis of the cardiac events in the trastuzumab adjuvant trials

scientific article published on 11 October 2019

Achievements in systemic therapies in the pregenomic era in metastatic breast cancer.

artículo científico publicado en 2007

Adjuvant Anti-HER2 Therapy, Treatment-Related Amenorrhea, and Survival in Premenopausal HER2-Positive Early Breast Cancer Patients

artículo científico publicado en 2019

Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial

artículo científico publicado en 2015

Adjuvant Letrozole and Tamoxifen Alone or Sequentially for Postmenopausal Women With Hormone Receptor-Positive Breast Cancer: Long-Term Follow-Up of the BIG 1-98 Trial

scientific article published on 26 November 2018

Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer

artículo científico publicado en 2017

Adjuvant chemotherapy in 2005: standards and beyond.

artículo científico publicado en 2005

Adjuvant trastuzumab: a 10-year overview of its benefit.

artículo científico publicado en 2016

An exploratory analysis of the factors leading to delays in cancer drug reimbursement in the European Union: the trastuzumab case.

artículo científico publicado en 2014

An update on PARP inhibitors--moving to the adjuvant setting

artículo científico

Analysis of regional timelines to set up a global phase III clinical trial in breast cancer: the adjuvant lapatinib and/or trastuzumab treatment optimization experience

artículo científico publicado en 2013

Angiogenesis and cancer: A cross-talk between basic science and clinical trials (the "do ut des" paradigm).

artículo científico publicado en 2006

Anthracycline and taxane-based chemotherapy versus docetaxel and cyclophosphamide in the adjuvant treatment of HER2-negative breast cancer patients: a systematic review and meta-analysis of randomized controlled trials

scientific article published on 21 November 2018

Are life-saving anticancer drugs reaching all patients? Patterns and discrepancies of trastuzumab use in the European Union and the USA.

artículo científico publicado en 2017

Are we HER-ting for innovation in neoadjuvant breast cancer trial design?

artículo científico publicado en 2009

Are we assuming too much with our statistical assumptions? Lessons learned from the ALTTO trial

scientific article published on 01 September 2019

Association of T-Cell Receptor Repertoire Use With Response to Combined Trastuzumab-Lapatinib Treatment of HER2-Positive Breast Cancer: Secondary Analysis of the NeoALTTO Randomized Clinical Trial

Association of p27 and Cyclin D1 Expression and Benefit from Adjuvant Trastuzumab Treatment in HER2-Positive Early Breast Cancer: A TransHERA Study.

artículo científico publicado en 2018

Atezolizumab in metastatic triple-negative breast cancer: IMpassion130 and 131 trials - how to explain different results?

artículo científico publicado en 2020

Bevacizumab and Breast Cancer: A Meta-Analysis of First-Line Phase III Studies and a Critical Reappraisal of Available Evidence

artículo científico publicado en 2012

Beyond trastuzumab: new treatment options for HER2-positive breast cancer

artículo científico

Beyond trastuzumab: overcoming resistance to targeted HER-2 therapy in breast cancer

artículo científico publicado en 2009

Biomarkers of response and resistance to PI3K inhibitors in estrogen receptor-positive breast cancer patients and combination therapies involving PI3K inhibitors

artículo científico publicado en 2019

Brain metastases in HER2-positive breast cancer: the evolving role of lapatinib

artículo científico publicado en 2009

Breast cancer treatment-induced cardiotoxicity

artículo científico publicado en 2017

Breast cancer: achievements in adjuvant systemic therapies in the pre-genomic era.

artículo científico publicado en 2006

CDK4/6 inhibition in HR-positive early breast cancer: are we putting all eggs in one basket?

scientific article published on 01 November 2020

CDK4/6 inhibitors in the treatment of patients with breast cancer: summary of a multidisciplinary round-table discussion

artículo científico publicado en 2018

CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: a retrospective substudy of the HERA trial (BIG 1-01).

artículo científico publicado en 2013

Cardiac assessment of early breast cancer patients 18 years after treatment with cyclophosphamide-, methotrexate-, fluorouracil- or epirubicin-based chemotherapy

artículo científico publicado en 2015

Cardiac biomarkers for early detection and prediction of trastuzumab and/or lapatinib-induced cardiotoxicity in patients with HER2-positive early-stage breast cancer: a NeoALTTO sub-study (BIG 1-06).

artículo científico publicado en 2017

Cardiac toxicity with anti-HER-2 therapies: what have we learned so far?

artículo científico publicado en 2009

Cardiotoxicity of systemic agents used in breast cancer

artículo científico

Cardiotoxicity of trastuzumab given for 12 months compared to shorter treatment periods: a systematic review and meta-analysis of six clinical trials

artículo científico publicado en 2020

Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology

scientific article published on January 2011

Career opportunities and benefits for young oncologists in the European Society for Medical Oncology (ESMO).

artículo científico publicado en 2016

Choice of chemotherapy regimen for early HER2-positive breast cancer in elderly patients

artículo científico publicado en 2017

Circulating Tumor DNA in HER2-Amplified Breast Cancer: A Translational Research Substudy of the NeoALTTO Phase III Trial

artículo científico publicado en 2019

Circulating tumor cells and response to neoadjuvant paclitaxel and HER2-targeted therapy: a sub-study from the NeoALTTO phase III trial.

artículo científico publicado en 2013

Clinical practice-changing trials: the HERA study paradigm.

artículo científico

Combination therapies for the treatment of HER2-positive breast cancer: current and future prospects.

artículo científico publicado en 2018

Comparison of a gene expression profiling strategy to standard clinical work-up for determination of tumour origin in cancer of unknown primary (CUP).

artículo científico publicado en 2013

Controversial issues in early-stage breast cancer: a global collaborative survey, supported by the European Society for Medical Oncology (ESMO)

artículo científico publicado en 2014

Controversies in oncology: which adjuvant endocrine therapy is to be given to premenopausal patients with hormone receptor-positive breast cancer?

artículo científico publicado en 2018

Corrigendum to “Menopausal hormone therapy use in 17 European countries during the last decade” [Maturitas 79 (2014) 287–291]

scholarly article published in Maturitas

Current perspectives of epothilones in breast cancer.

artículo científico publicado en 2008

Denosumab in early-stage breast cancer

artículo científico publicado en 2019

Discrepancies in cancer incidence and mortality and its relationship to health expenditure in the 27 European Union member states.

artículo científico publicado en 2013

Disease-free survival according to degree of HER2 amplification for patients treated with adjuvant chemotherapy with or without 1 year of trastuzumab: the HERA Trial

artículo científico publicado en 2009

Dissecting the effect of hormone receptor status in patients with HER2-positive early breast cancer: exploratory analysis from the ALTTO (BIG 2-06) randomized clinical trial

artículo científico publicado en 2019

Dissecting the heterogeneity of triple-negative breast cancer

artículo científico

Dual human epidermal growth factor receptor 2 blockade: another step forward in treating patients with human epidermal growth factor receptor 2-positive breast cancer

artículo científico publicado en 2012

Duration of endocrine therapy and its impact on the results of adjuvant trials in premenopausal breast cancer patients

artículo científico publicado en 2015

ER+/HER2+ breast cancer: are we really de-escalating?

scientific article published on 01 June 2019

ESMO Management and treatment adapted recommendations in the COVID-19 era: Breast Cancer

scientific article published on 01 May 2020

Early Modulation of Circulating MicroRNAs Levels in HER2-Positive Breast Cancer Patients Treated with Trastuzumab-Based Neoadjuvant Therapy

artículo científico publicado en 2020

Effects of Estrogen Receptor and Human Epidermal Growth Factor Receptor-2 Levels on the Efficacy of Trastuzumab: A Secondary Analysis of the HERA Trial

artículo científico

Efficacy of Adjuvant Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer and Tumors ≤ 2 cm: A Meta-Analysis of the Randomized Trastuzumab Trials

artículo científico publicado en 2015

Efficacy of Anti-HER2 Agents in Combination With Adjuvant or Neoadjuvant Chemotherapy for Early and Locally Advanced HER2-Positive Breast Cancer Patients: A Network Meta-Analysis.

artículo científico publicado en 2018

Emerging treatments for HER2-positive early-stage breast cancer: focus on neratinib.

artículo científico publicado en 2017

End-of-life care: the red alert for physicians

artículo científico publicado en 2006

Endocrine therapy and palbociclib within a compassionate use program in heavily pretreated hormone receptor-positive, HER2-negative metastatic breast cancer.

artículo científico publicado en 2018

Endocrine therapy-based treatments in hormone receptor-positive/HER2-negative advanced breast cancer: systematic review and network meta-analysis

artículo científico publicado en 2020

Factors affecting surgical management following neoadjuvant therapy in patients with primary HER2-positive breast cancer: results from the NeoALTTO phase III trial.

artículo científico publicado en 2014

Facts and controversies in the use of trastuzumab in the adjuvant setting

artículo científico publicado en 2008

Feasibility Study of EndoTAG-1, a Tumor Endothelial Targeting Agent, in Combination with Paclitaxel followed by FEC as Induction Therapy in HER2-Negative Breast Cancer

artículo científico publicado en 2016

Final 10-year results of the Breast International Group 2-98 phase III trial and the role of Ki67 in predicting benefit of adjuvant docetaxel in patients with oestrogen receptor positive breast cancer.

artículo científico publicado en 2015

Genome-wide gene expression profiling to predict resistance to anthracyclines in breast cancer patients

artículo científico publicado en 2013

Genomic Grade Index (GGI): feasibility in routine practice and impact on treatment decisions in early breast cancer

artículo científico publicado en 2013

Genomic grade adds prognostic value in invasive lobular carcinoma.

artículo científico publicado en 2012

Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials).

artículo científico publicado en 2015

Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)†

artículo científico publicado en 2015

HER-2 as a target for breast cancer therapy.

artículo científico publicado en 2009

HER-2 positive breast cancer: what else beyond trastuzumab-based therapy?

artículo científico publicado en 2008

HER2-overexpressing breast cancer: time for the cure with less chemotherapy?

artículo científico publicado en 2011

HER2-positive breast cancer is lost in translation: time for patient-centered research

artículo científico publicado en 2017

High HER2 expression correlates with response to the combination of lapatinib and trastuzumab.

artículo científico publicado en 2014

How Long is Enough - Optimal Timing of Anti-HER2/neu Therapy in the Adjuvant Setting in Early Breast Cancer

artículo científico publicado en 2013

Hurdles and delays in access to anti-cancer drugs in Europe.

artículo científico publicado en 2014

I-SPY 2: optimising cancer drug development in the 21st century.

artículo científico publicado en 2016

Immune response to anti-SARS-CoV-2 prime-vaccination in patients with cancer: a systematic review and meta-analysis

artículo científico publicado en 2022

Impact of Diabetes, Insulin, and Metformin Use on the Outcome of Patients With Human Epidermal Growth Factor Receptor 2-Positive Primary Breast Cancer: Analysis From the ALTTO Phase III Randomized Trial.

artículo científico publicado en 2017

Impact of ovarian function suppression in premenopausal women with estrogen receptor-positive early breast cancer

artículo científico publicado en 2019

Impact of solid cancer on in-hospital mortality overall and among different subgroups of patients with COVID-19: a nationwide, population-based analysis

scientific article published on 01 September 2020

Improving quality of life after breast cancer: dealing with symptoms

artículo científico publicado en 2011

In Reply to Belkacemi and Tsoutsou

scientific article published on 01 October 2018

Information perception, wishes, and satisfaction in ambulatory cancer patients under active treatment: patient-reported outcomes with QLQ-INFO25.

artículo científico publicado en 2014

International expert consensus on primary systemic therapy in the management of early breast cancer: highlights of the Fourth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2010).

artículo científico

Intrathecal administration of trastuzumab for the treatment of meningeal carcinomatosis in HER2-positive metastatic breast cancer: a systematic review and pooled analysis

artículo científico publicado en 2013

Jumping higher: is it still possible? The ALTTO trial challenge

artículo científico publicado en 2008

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial

artículo científico publicado en 2012

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response

artículo científico publicado en 2014

Lapatinib-Related Rash and Breast Cancer Outcome in the ALTTO Phase III Randomized Trial

artículo científico publicado en 2016

Larotaxel: broadening the road with new taxanes

artículo científico publicado en 2009

Lessons learned at SABCS 2019 and to-dos from immunotherapy in breast cancer

scientific article published on 01 March 2020

Long-term Safety of Pregnancy Following Breast Cancer According to Estrogen Receptor Status.

artículo científico publicado en 2017

Long-term benefit of high-dose epirubicin in adjuvant chemotherapy for node-positive breast cancer: 15-year efficacy results of the Belgian multicentre study.

artículo científico publicado en 2008

Long-term toxic effects of adjuvant chemotherapy in breast cancer.

artículo científico publicado en 2011

Longer-term assessment of trastuzumab-related cardiac adverse events in the Herceptin Adjuvant (HERA) trial.

artículo científico publicado en 2010

Luminal B breast cancer: molecular characterization, clinical management, and future perspectives

artículo científico publicado en 2014

Magnitude of trastuzumab benefit in patients with HER2-positive, invasive lobular breast carcinoma: results from the HERA trial

artículo científico publicado en 2013

Male breast cancer: finding the way in this uncommon path.

artículo científico publicado en 2017

Menopausal hormone therapy use in 17 European countries during the last decade

article by Lieveke Ameye et al published November 2014 in Maturitas

Menopausal hormone therapy use in relation to breast cancer incidence in 11 European countries

artículo científico publicado en 2015

Metronomic chemotherapy combined with endocrine therapy: are we challenging some dogmas?

artículo científico publicado en 2020

Molecular Profiling of a Tumor of Unknown Origin

artículo científico publicado en 2006

Molecular markers of head and neck squamous cell carcinoma: promising signs in need of prospective evaluation

artículo científico publicado en 2006

Molecular targeted therapies in breast cancer: where are we now?

artículo científico publicado en 2007

Motherhood after breast cancer: searching for la dolce vita.

artículo científico publicado en 2011

Multifactorial approach to predicting resistance to anthracyclines

artículo científico publicado en 2011

Neoadjuvant Chemotherapy and Targeted Therapies: a Promising Strategy

artículo científico publicado en 2011

Neoadjuvant anthracycline and trastuzumab for breast cancer: is concurrent treatment safe?

artículo científico publicado en 2011

Neoadjuvant chemotherapy and trastuzumab versus neoadjuvant chemotherapy followed by post-operative trastuzumab for patients with HER2-positive breast cancer

artículo científico publicado en 2015

Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 tri

scientific article published on 08 August 2019

Novel therapeutics in breast cancer—Looking to the future

OPTIMOX1 in Advanced Colorectal Cancer: Lack of Evidence for a Stop-and-Go Strategy

article

Oncofertility counselling in premenopausal women with HER2-positive breast cancer

Ovarian Function Suppression in Premenopausal Women with Early-Stage Breast Cancer.

artículo científico publicado en 2017

Overall survival benefit for sequential doxorubicin–docetaxel compared with concurrent doxorubicin and docetaxel in node-positive breast cancer—8-year results of the Breast International Group 02-98 phase III trial†

artículo científico publicado en 2013

PERSEPHONE - implications for clinical practice in 2019

artículo científico publicado en 2019

PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancer

artículo científico publicado en 2015

Pattern of rash, diarrhea, and hepatic toxicities secondary to lapatinib and their association with age and response to neoadjuvant therapy: analysis from the NeoALTTO trial

artículo científico publicado en 2013

Pertuzumab in HER2-positive early breast cancer: current use and perspectives

scientific article published on 02 April 2019

Pharmacologic measures in the prevention of left ventricular dysfunction associated with molecular-targeted therapies in the treatment of cancer patients

artículo científico publicado en 2017

Phase I trial combining temozolomide plus lapatinib for the treatment of brain metastases in patients with HER2-positive metastatic breast cancer: the LAPTEM trial.

artículo científico publicado en 2013

Phosphoethanolamine and the danger of unproven drugs

artículo científico publicado en 2016

Planning cancer control in Latin America and the Caribbean

artículo científico publicado en 2013

Plasma miRNA Levels for Predicting Therapeutic Response to Neoadjuvant Treatment in HER2-positive Breast Cancer: Results from the NeoALTTO Trial

scientific article published on 27 February 2019

Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis

artículo científico publicado en 2018

Post-neoadjuvant treatment and the management of residual disease in breast cancer: state of the art and perspectives

scientific article published on 25 February 2019

Postmastectomy Radiation Therapy in Women with T1-T2 Tumors and 1 to 3 Positive Lymph Nodes: Analysis of the Breast International Group 02-98 Trial

artículo científico publicado en 2018

Pregnancies during and after trastuzumab and/or lapatinib in patients with human epidermal growth factor receptor 2-positive early breast cancer: analysis from the NeoALTTO (BIG 1-06) and ALTTO (BIG 2-06) trials

scientific article published on 18 October 2018

Pregnancy occurring during or following adjuvant trastuzumab in patients enrolled in the HERA trial (BIG 01-01).

artículo científico publicado en 2012

Prevention, Monitoring, and Management of Cardiac Dysfunction in Patients with Metastatic Breast Cancer

scientific article published on 07 May 2019

Professional burnout in European young oncologists: results of the European Society for Medical Oncology (ESMO) Young Oncologists Committee Burnout Survey.

artículo científico publicado en 2017

Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trial

artículo científico publicado en 2012

Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98

artículo científico publicado en 2013

Prognostic impact of pregnancy after breast cancer according to estrogen receptor status: a multicenter retrospective study

artículo científico publicado en 2012

Prognostic role of distant disease-free interval from completion of adjuvant trastuzumab in HER2-positive early breast cancer: analysis from the ALTTO (BIG 2-06) trial

artículo científico publicado en 2020

Prognostic, predictive abilities and concordance of BCL2 and TP53 protein expression in primary breast cancers and axillary lymph-nodes: a retrospective analysis of the Belgian three arm study evaluating anthracycline vs CMF adjuvant chemotherapy

artículo científico publicado en 2014

Pulmonary epithelial permeability in patients treated with bleomycin containing chemotherapy detected by technetium-99m diethylene triamine penta-acetic acid aerosol (99mTc-DTPA) scintigraphy

artículo científico publicado en 2005

RNA Sequencing to Predict Response to Neoadjuvant Anti-HER2 Therapy: A Secondary Analysis of the NeoALTTO Randomized Clinical Trial.

artículo científico

Radiological evaluation of response to immunotherapy in brain tumors: Where are we now and where are we going?

scholarly article by Michele Porcu et al published June 2018 in Critical Reviews in Oncology Hematology

Recurrence dynamics of breast cancer according to baseline body mass index

artículo científico publicado en 2017

Regional Nodal Irradiation After Breast Conserving Surgery for Early HER2-Positive Breast Cancer: Results of a Subanalysis From the ALTTO Trial.

artículo científico publicado en 2017

Reply to C. Fontanella et al.

artículo científico publicado en 2014

Reproductive potential and performance of fertility preservation strategies in BRCA-mutated breast cancer patients

artículo científico publicado en 2017

Review: side effects of approved molecular targeted therapies in solid cancers.

artículo científico publicado en 2007

Risk factors for the development of brain metastases in patients with HER2-positive breast cancer

article

Risk of adverse events with the addition of targeted agents to endocrine therapy in patients with hormone receptor-positive metastatic breast cancer: A systematic review and meta-analysis.

artículo científico publicado en 2017

Role of Troponins I and T and N-Terminal Prohormone of Brain Natriuretic Peptide in Monitoring Cardiac Safety of Patients With Early-Stage Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Receiving Trastuzumab: A Herceptin Adjuvant St

artículo científico publicado en 2016

Role of the multidisciplinary team in breast cancer management: results from a large international survey involving 39 countries.

artículo científico publicado en 2011

Sequential or Concurrent Administration of Trastuzumab in Early Breast Cancer? Too Early to Judge

article published in 2010

Shrinking the tumor, shrinking the patient sample size: the early disclosure dilemma

artículo científico publicado en 2005

Single-agent PARP inhibitors for the treatment of patients with BRCA-mutated HER2-negative metastatic breast cancer: a systematic review and meta-analysis.

artículo científico publicado en 2018

Supportive care after curative treatment for breast cancer (survivorship care): resource allocations in low- and middle-income countries. A Breast Health Global Initiative 2013 consensus statement

artículo científico publicado en 2013

Surgery of the primary tumour in patients presenting with de novo metastatic breast cancer: to do or not to do?

artículo científico publicado en 2018

Survival outcomes of the NeoALTTO study (BIG 1-06): updated results of a randomised multicenter phase III neoadjuvant clinical trial in patients with HER2-positive primary breast cancer

artículo científico publicado en 2019

Targeted therapies in breast cancer: are heart and vessels also being targeted?

artículo científico publicado en 2012

Targeted therapy for breast cancer in older patients

artículo científico publicado en 2019

Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer

artículo científico publicado en 2013

The 17q12-q21 amplicon: Her2 and topoisomerase-IIalpha and their importance to the biology of solid tumours.

artículo científico publicado en 2006

The 41-gene classifier TRAR predicts response of HER2 positive breast cancer patients in the NeoALTTO study

scientific article published on 05 July 2019

The Prognostic Role of Androgen Receptor in Patients with Early-Stage Breast Cancer: A Meta-analysis of Clinical and Gene Expression Data

artículo científico publicado en 2016

The effect of body mass index on overall and disease-free survival in node-positive breast cancer patients treated with docetaxel and doxorubicin-containing adjuvant chemotherapy: the experience of the BIG 02-98 trial

artículo científico publicado en 2010

The impact of cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) on the incidence of alopecia in patients with metastatic breast cancer (BC)

artículo científico publicado en 2020

The landscape of medical oncology in Europe by 2020.

artículo científico publicado en 2014

The new generation of breast cancer clinical trials: the right drug for the right target

artículo científico publicado en 2008

The prognostic performance of Adjuvant! Online and Nottingham Prognostic Index in young breast cancer patients.

artículo científico publicado en 2016

The use of breast imaging for predicting response to neoadjuvant lapatinib, trastuzumab and their combination in HER2-positive breast cancer: Results from Neo-ALTTO.

artículo científico publicado en 2017

Threat posed by unproven drugs in medical oncology

artículo científico publicado en 2016

Trastuzumab (herceptin) for early-stage breast cancer

artículo científico publicado en 2007

Trastuzumab for early breast cancer: current status and future directions.

artículo científico publicado en 2007

Trastuzumab for patients with HER2 positive breast cancer: delivery, duration and combination therapies.

artículo científico

Trastuzumab re-treatment following adjuvant trastuzumab and the importance of distant disease-free interval: the HERA trial experience

artículo científico publicado en 2015

Trastuzumab-associated cardiac events at 8 years of median follow-up in the Herceptin Adjuvant trial (BIG 1-01).

artículo científico publicado en 2014

Treatment Options in Anthracycline and/or Taxane Pretreated Patients with Metastatic Breast Cancer

Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial

artículo científico

Tumor-infiltrating lymphocytes in patients with HER2-positive breast cancer treated with neoadjuvant chemotherapy plus trastuzumab, lapatinib or their combination: A meta-analysis of randomized controlled trials

artículo científico publicado en 2017

Tumour-infiltrating lymphocytes in non-invasive breast cancer: A systematic review and meta-analysis

scientific article published on 09 July 2021

Twenty years of anti-HER2 therapy-associated cardiotoxicity

artículo científico publicado en 2016

Use of adjuvant chemotherapy (CT) and radiotherapy (RT) in incompletely resected (R1) early stage Non-Small Cell Lung Cancer (NSCLC): a European survey conducted by the European Society for Medical Oncology (ESMO) young oncologists committee.

artículo científico publicado en 2014

Weekly carboplatin plus neoadjuvant anthracycline-taxane-based regimen in early triple-negative breast cancer: a prospective phase II trial by the Breast Cancer Task Force of the Belgian Society of Medical Oncology (BSMO)

scientific article published on 08 May 2019

[Non-Hodgkin's lymphoma in the thyroid: case report]

scientific article published on 01 June 2004

p-STAT3 in luminal breast cancer: Integrated RNA-protein pooled analysis and results from the BIG 2-98 phase III trial.

artículo científico publicado en 2017

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda